OTCMKTS:GNMSF Genmab A/S Q2 2025 Earnings Results & Report $367.00 0.00 (0.00%) As of 10/9/2026 10:28 AM Eastern Genmab A/S beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 7, 2025. The company reported EPS of $5.42 versus the $3.99 consensus estimate, while revenue of $925.00 million fell short of the $949.06 million estimate by $24.06 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeAfter Market Closes Genmab A/S EPS ResultsActual EPS$5.42Consensus EPS $3.99Beat/MissBeat by +$1.43One Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersGenmab A/S Revenue ResultsActual Revenue$925.00 millionExpected Revenue$949.06 millionBeat/MissMissed by -$24.06 millionYoY Revenue GrowthN/AUpcoming EarningsGenmab A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Genmab A/S Q2 2025 Earnings FAQ Did Genmab A/S beat earnings estimates for Q2 2025? Genmab A/S (OTCMKTS:GNMSF) reported earnings of $5.42 per share for Q2 2025, beating the consensus estimate of $3.99. The report was announced on Thursday, August 7, 2025. What was Genmab A/S' revenue for Q2 2025? Genmab A/S reported revenue of $925.00 million for Q2 2025, against a consensus estimate of $949.06 million. When is Genmab A/S' next earnings date? Genmab A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genmab A/S on the company's earnings history page. Genmab A/S Earnings HeadlinesGenmab Grants Restricted Stock Units to Board After Extraordinary General MeetingOctober 7, 2026 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's What HappenedOctober 6, 2026 | americanbankingnews.comPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.October 12 at 1:00 AM | Monument Traders Alliance (Ad)GMAB jumps as Genmab posts positive Phase 3 lymphoma dataOctober 5, 2026 | quiverquant.comQGenmab A/S (OTCMKTS:GNMSF) Sets New 12-Month High - What's Next?October 5, 2026 | americanbankingnews.comGenmab Discloses Darwin Global as 5.11% Major ShareholderOctober 2, 2026 | tipranks.comSee More Genmab A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email. Email Address About Genmab A/SGenmab A/S (OTCMKTS:GNMSF) is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes. Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies. Its research and development activities have contributed to medicines including DARZALEX (daratumumab) for multiple myeloma, RYBREVANT (amivantamab) for certain lung cancers, and EPKINLY (epcoritamab) for certain B-cell lymphomas. Genmab has developed these and other products through collaborations with global pharmaceutical companies, including Johnson & Johnson and AbbVie. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through research, development, partnerships and commercialization activities in Europe, North America and other regions. The company is led by President and Chief Executive Officer Jan van de Winkel, who has been associated with Genmab’s leadership since the company’s early development.View Genmab A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
